NASDAQ:ICLR

ICON Public - ICLR Stock Forecast, Price & News

$211.93

-2.76 (-1.29%)

(As of 11/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $211.68
▼
$218.16
50-Day Range: $173.90
▼
$224.80
52-Week Range: $171.43
▼
$313.00

Volume: 533,679 shs
Average Volume: 566,819 shs
Market Capitalization: $17.25 billion

P/E Ratio: 37.64
Dividend Yield: N/A
Price Target: $262.80

ICON Public MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 24.0% Upside
$262.80 Price Target
Short Interest: Healthy
1.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 6.87%
From $10.62 to $11.35 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

72nd out of 1,038 stocks

Commercial Physical Research Industry

3rd out of 16 stocks

3.4

Analyst's Opinion

Consensus Rating
ICON Public has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $262.80, ICON Public has a forecasted upside of 24.0% from its current price of $211.93.
Amount of Analyst Coverage
ICON Public has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
1.06% of the outstanding shares of ICON Public have been sold short.
Short Interest Ratio / Days to Cover
ICON Public has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ICON Public has recently decreased by 32.31%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ICON Public does not currently pay a dividend.
Dividend Growth
ICON Public does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ICLR.

2.4

News and Social Media Coverage

News Sentiment
ICON Public has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ICON Public this week, compared to 2 articles on an average week.
MarketBeat Follows
1 people have added ICON Public to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ICON Public insiders have not sold or bought any company stock.
Percentage Held by Insiders
44.00% of the stock of ICON Public is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.28% of the stock of ICON Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for ICON Public are expected to grow by 6.87% in the coming year, from $10.62 to $11.35 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ICON Public is 37.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.00.
Price to Earnings Ratio vs. Sector
The P/E ratio of ICON Public is 37.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.12.
Price to Earnings Growth Ratio
ICON Public has a PEG Ratio of 1.43. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
ICON Public has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ICON Public (NASDAQ:ICLR) Stock

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Stock News Headlines

November 29, 2022 | finance.yahoo.com

Calculating The Intrinsic Value Of ICON Public Limited Company (NASDAQ:ICLR)

November 25, 2022 | reuters.com

ICLR.OQ - ICON PLC | Stock Price & Latest News | Reuters

November 24, 2022 | finance.yahoo.com

ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference

November 22, 2022 | americanbankingnews.com

ICON Public Limited (NASDAQ:ICLR) Receives $262.80 Consensus Price Target from Analysts

November 6, 2022 | seekingalpha.com

ICON Public Limited Company (ICLR) Q3 2022 Earnings Call Transcript

November 4, 2022 | markets.businessinsider.com

Mizuho Securities Reaffirms Their Buy Rating on Icon (ICLR)

November 2, 2022 | finance.yahoo.com

Do You Think ICON Public Limited Company (ICLR) is a High Quality Company?

November 2, 2022 | finance.yahoo.com

ICON Reports Third Quarter 2022 Results

November 1, 2022 | reuters.com

ICLR.O - ICON PLC | Stock Price & Latest News | Reuters

October 24, 2022 | finance.yahoo.com

Is ICON Public Limited Company (ICLR) a Fundamentally Strong Stock to Invest In?

October 18, 2022 | finance.yahoo.com

Strength Seen in Icon PLC (ICLR): Can Its 5.3% Jump Turn into More Strength?

October 17, 2022 | finance.yahoo.com

The five-year decline in earnings might be taking its toll on ICON (NASDAQ:ICLR) shareholders as stock falls 6.8% over the past week

October 6, 2022 | finanznachrichten.de

ICON plc: ICON selected by BARDA to conduct anthrax vaccine clinical trial

October 6, 2022 | msn.com

Analyst Ratings for Icon

October 6, 2022 | finance.yahoo.com

ICON selected by BARDA to conduct anthrax vaccine clinical trial

October 4, 2022 | nasdaq.com

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 42%?

September 26, 2022 | fool.com.au

ICON Public Limited Company (NASDAQ: ICLR) Share Price and News

September 26, 2022 | finance.yahoo.com

ICON plc Schedules Third Quarter 2022 Earnings Conference Call

September 22, 2022 | nasdaq.com

Interesting ICLR Put And Call Options For November 18th

September 21, 2022 | finance.yahoo.com

Are ICON Public Limited Company's (NASDAQ:ICLR) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

September 14, 2022 | msn.com

What 6 Analyst Ratings Have To Say About Icon

September 13, 2022 | finance.yahoo.com

Icon PLC (ICLR) Surges 3%: Is This an Indication of Further Gains?

September 6, 2022 | finance.yahoo.com

ICON Releases its 2021 ESG Report

September 2, 2022 | nasdaq.com

Despite lower earnings than five years ago, ICON (NASDAQ:ICLR) investors are up 79% since then

August 31, 2022 | finance.yahoo.com

ICON plc to Present at the 2022 Wells Fargo Healthcare Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Company Calendar

Last Earnings: 11/03/2021
Today: 11/29/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/28/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ICLR
CUSIP: N/A
CIK: 1060955
Web: www.iconplc.com
Phone: (531) 291-2000
Fax: 353-1247-6260
Employees: 38,330
Year Founded: 1990

Price Target and Rating

Average Stock Price Forecast: $262.80
High Stock Price Forecast: $290.00
Low Stock Price Forecast: $215.00
Forecasted Upside/Downside: +24.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.63
Trailing P/E Ratio: 37.64
Forward P/E Ratio: 19.96
P/E Growth: 1.43
Net Income: $153.18 million
Net Margins: 6.06%
Pretax Margin: 6.93%
Return on Equity: 10.75%
Return on Assets: 5.09%

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 1.16
Quick Ratio: 1.16

Sales & Book Value

Annual Sales: $5.48 billion
Price / Sales: 3.15
Cash Flow: $11.09 per share
Price / Cash Flow: 19.11
Book Value: $99.11 per share
Price / Book: 2.14

Miscellaneous

Outstanding Shares: 81,390,000
Free Float: 45,578,000
Market Cap: $17.25 billion
Optionable: Optionable
Beta: 1.01

Social Links

Key Executives

Dr. Steven A. Cutler MBA (Age 62)
Ph.D., CEO & Director
Comp: $3.64M

Mr. Brendan Brennan (Age 43)
Chief Financial Officer
Comp: $1.63M

Jonathan Curtain
Sr. VP of Corp. & Commercial Fin.

Mr. Thomas N. O'Leary
Chief Information Officer

Mr. Diarmaid Cunningham (Age 47)
Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec.

Mr. Simon Holmes (Age 55)
Exec. VP of Investor Relations & Corp. Devel.

Ms. Niamh Murphy
Director of Corp. Communications

Mr. David Green
VP of Marketing

Mr. Joe Cronin
Chief HR Officer

Ms. Dana Lynn Poff Snr.
Exec. VP of Program Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ICLR Stock - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings or view top-rated stocks.
What is ICON Public's stock price forecast for 2023?: 11 Wall Street analysts have issued 12-month price targets for ICON Public's shares. Their ICLR share price forecasts range from $215.00 to $290.00. On average, they predict the company's stock price to reach $262.80 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price.
View analysts price targets for ICLR or view top-rated stocks among Wall Street analysts.
How have ICLR shares performed in 2022?: ICON Public's stock was trading at $309.70 at the beginning of 2022. Since then, ICLR stock has decreased by 30.4% and is now trading at $215.45.
View the best growth stocks for 2022 here.
When is ICON Public's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our ICLR earnings forecast.
How were ICON Public's earnings last quarter?: ICON Public Limited (NASDAQ:ICLR) released its quarterly earnings results on Wednesday, November, 3rd. The medical research company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.16. The medical research company earned $1.87 billion during the quarter, compared to analyst estimates of $1.84 billion. ICON Public had a net margin of 6.06% and a trailing twelve-month return on equity of 10.75%. ICON Public's revenue for the quarter was up 166.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.72 earnings per share.
What guidance has ICON Public issued on next quarter's earnings?: ICON Public updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $11.65-$11.85 for the period, compared to the consensus earnings per share estimate of $11.66. The company issued revenue guidance of $7.69 billion-$7.81 billion, compared to the consensus revenue estimate of $7.74 billion.
What is Steve Cutler's approval rating as ICON Public's CEO?: 147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).
What is ICON Public's stock symbol?: ICON Public trades on the NASDAQ under the ticker symbol "ICLR."
Who are ICON Public's major shareholders?: ICON Public's stock is owned by many different institutional and retail investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.34%), Todd Asset Management LLC (0.17%), Kornitzer Capital Management Inc. KS (0.04%), Captrust Financial Advisors (0.03%), Russell Investments Group Ltd. (0.03%) and FDx Advisors Inc. (0.01%).
How do I buy shares of ICON Public?: Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ICON Public's stock price today?: One share of ICLR stock can currently be purchased for approximately $215.45.
How much money does ICON Public make?: ICON Public (NASDAQ:ICLR) has a market capitalization of $17.54 billion and generates $5.48 billion in revenue each year. The medical research company earns $153.18 million in net income (profit) each year or $5.63 on an earnings per share basis.
How many employees does ICON Public have?: The company employs 38,330 workers across the globe.
Does ICON Public have any subsidiaries?: The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
How can I contact ICON Public?: ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The official website for the company is www.iconplc.com. The medical research company can be reached via phone at (531) 291-2000 or via fax at 353-1247-6260.

This page (NASDAQ:ICLR) was last updated on 11/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial